WO2022152315A1 - 一种合成氨基嘧啶类fak抑制剂化合物的方法 - Google Patents
一种合成氨基嘧啶类fak抑制剂化合物的方法 Download PDFInfo
- Publication number
- WO2022152315A1 WO2022152315A1 PCT/CN2022/072552 CN2022072552W WO2022152315A1 WO 2022152315 A1 WO2022152315 A1 WO 2022152315A1 CN 2022072552 W CN2022072552 W CN 2022072552W WO 2022152315 A1 WO2022152315 A1 WO 2022152315A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- methyl
- sodium
- solvent
- base
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 78
- 229940124783 FAK inhibitor Drugs 0.000 title claims abstract description 13
- 150000005005 aminopyrimidines Chemical class 0.000 title claims abstract description 10
- 238000001308 synthesis method Methods 0.000 title abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract description 11
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 74
- 238000006243 chemical reaction Methods 0.000 claims description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 40
- 239000002585 base Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 35
- -1 carboxylic acid compound Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 24
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 18
- 238000010511 deprotection reaction Methods 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 14
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 14
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 14
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 12
- 125000005626 carbonium group Chemical group 0.000 claims description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 11
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 11
- 239000003054 catalyst Substances 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 11
- 235000011181 potassium carbonates Nutrition 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000006482 condensation reaction Methods 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 8
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 230000001035 methylating effect Effects 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 8
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 claims description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 5
- 235000017550 sodium carbonate Nutrition 0.000 claims description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- CZHYKKAKFWLGJO-UHFFFAOYSA-N dimethyl phosphite Chemical compound COP([O-])OC CZHYKKAKFWLGJO-UHFFFAOYSA-N 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- LFQSCWFLJHTTHZ-LIDOUZCJSA-N ethanol-d6 Chemical compound [2H]OC([2H])([2H])C([2H])([2H])[2H] LFQSCWFLJHTTHZ-LIDOUZCJSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 150000007970 thio esters Chemical group 0.000 claims description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 2
- RIFYBDSTDAXCRY-UHFFFAOYSA-N 2,2-dimethoxyethoxyalumane Chemical compound COC(CO[AlH2])OC RIFYBDSTDAXCRY-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012448 Lithium borohydride Substances 0.000 claims description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 claims description 2
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 claims description 2
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 claims description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000085 borane Inorganic materials 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 claims description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 2
- GMLFPSKPTROTFV-UHFFFAOYSA-N dimethylborane Chemical compound CBC GMLFPSKPTROTFV-UHFFFAOYSA-N 0.000 claims description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 claims description 2
- RMNJNEUWTBBZPT-UHFFFAOYSA-N methyl 4-nitrobenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 RMNJNEUWTBBZPT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012022 methylating agents Substances 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical group CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical group 0.000 claims description 2
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 claims description 2
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- KWZWNVAHEQHCTQ-UHFFFAOYSA-N diacetyloxyboranyl acetate Chemical compound CC(=O)OB(OC(C)=O)OC(C)=O KWZWNVAHEQHCTQ-UHFFFAOYSA-N 0.000 claims 1
- WILVYLQMYNGFSH-UHFFFAOYSA-N ethanamine;n-ethylethanamine Chemical compound CCN.CCNCC WILVYLQMYNGFSH-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 claims 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 239000000047 product Substances 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 239000012467 final product Substances 0.000 abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000005711 Benzoic acid Substances 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 7
- 235000010233 benzoic acid Nutrition 0.000 description 7
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 6
- 229950008937 defactinib Drugs 0.000 description 5
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- TZZPXCFAAWHGCA-UHFFFAOYSA-N tert-butyl 4-[[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(Cl)=N1 TZZPXCFAAWHGCA-UHFFFAOYSA-N 0.000 description 4
- VJAIKYBSGGFORH-UHFFFAOYSA-N N-(3-cyanopyrazin-2-yl)methanesulfonamide Chemical compound CS(NC1=NC=CN=C1C#N)(=O)=O VJAIKYBSGGFORH-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- BGVJHAYXHSRENE-UHFFFAOYSA-N n-(3-cyanopyrazin-2-yl)-n-methylmethanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=NC=CN=C1C#N BGVJHAYXHSRENE-UHFFFAOYSA-N 0.000 description 3
- IETKYMZYQKEXLW-UHFFFAOYSA-N n-[3-(aminomethyl)pyrazin-2-yl]-n-methylmethanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=NC=CN=C1CN IETKYMZYQKEXLW-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SDLFAEGTVBPHBK-UHFFFAOYSA-N 3-chloropyrazine-2-carbonitrile Chemical compound ClC1=NC=CN=C1C#N SDLFAEGTVBPHBK-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- CDVWUXDPGJDJGH-UHFFFAOYSA-N N,N-diethylethanamine ethane-1,2-diamine Chemical compound C(C)N(CC)CC.C(CN)N CDVWUXDPGJDJGH-UHFFFAOYSA-N 0.000 description 1
- BGVJHAYXHSRENE-FIBGUPNXSA-N N-(3-cyanopyrazin-2-yl)-N-(trideuteriomethyl)methanesulfonamide Chemical compound [2H]C([2H])([2H])N(C1=NC=CN=C1C#N)S(C)(=O)=O BGVJHAYXHSRENE-FIBGUPNXSA-N 0.000 description 1
- IETKYMZYQKEXLW-FIBGUPNXSA-N N-[3-(aminomethyl)pyrazin-2-yl]-N-(trideuteriomethyl)methanesulfonamide Chemical compound [2H]C([2H])([2H])N(C1=NC=CN=C1CN)S(C)(=O)=O IETKYMZYQKEXLW-FIBGUPNXSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SGUNODQGWJUTBK-UHFFFAOYSA-N aniline N-methylmethanamine Chemical compound NC1=CC=CC=C1.CNC SGUNODQGWJUTBK-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- ORPJQSFBLBHKPN-UHFFFAOYSA-N dichloromethane;methylsulfinylmethane Chemical compound ClCCl.CS(C)=O ORPJQSFBLBHKPN-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- RAIWYFYCHWDSOE-UHFFFAOYSA-N n,n-di(propan-2-yl)butan-2-amine Chemical compound CCC(C)N(C(C)C)C(C)C RAIWYFYCHWDSOE-UHFFFAOYSA-N 0.000 description 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical group [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical group [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- KYORUZMJUKHKFS-UHFFFAOYSA-N tert-butyl 4-aminobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(N)C=C1 KYORUZMJUKHKFS-UHFFFAOYSA-N 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to the field of drug synthesis, in particular to a method for synthesizing aminopyrimidine FAK inhibitor compounds.
- Defactinib (VS-6063), developed by Verastem, is a selective and orally effective FAK inhibitor with the structural formula of Clinical trials are currently underway.
- Patent CN110452229A discloses a deuterated Defactinib compound
- Patent CN111377871A discloses a FAK inhibitor and its combination drug. The emergence of these patents has improved more options for the research of FAK inhibitors.
- the object of the present invention is to provide a better method for synthesizing aminopyrimidine FAK inhibitor compounds.
- the invention provides a method for synthesizing aminopyrimidine FAK inhibitor compounds, which comprises the following steps:
- Step (1) using compound (I) as a raw material, under the action of a base, react with 2,4-dichloro-5-(trifluoromethyl)pyrimidine in a solvent to obtain compound (II), wherein R 1 is Hydrogen or carboxylic acid protecting groups;
- Step (2) in a solvent, compound (II) is reacted with compound (III) under the action of a base to obtain compound (IV), wherein R 2 is selected from C 1 -C 6 alkyl or C 1 -C 6 deuterated alkyl, R3 and R4 are independently selected from hydrogen or deuterium ;
- Step (3) compound (IV) is subjected to deprotection reaction to obtain carboxylic acid compound (V);
- step (1) the molar ratio of compound (I), 2,4-dichloro-5-(trifluoromethyl)pyrimidine and base is (1-3): (1-3): (1 to 7);
- step (2) the molar ratio of the compound (II), the compound (III) and the base is (1-5): (0.1-1): (1-5);
- step (4) the molar ratio of (V) and compound (VI) is (1-5): (1-5);
- step (1) the molar ratio of compound (I), 2,4-dichloro-5-(trifluoromethyl)pyrimidine and base is 2.0:2.1:6.4;
- step (2) the molar ratio of compound (II), compound (III) and base is 1:0.5:1.5;
- step (4) the molar ratio of (V) and compound (VI) is 1:1.1.
- step (1) the reaction temperature is -20°C to 150°C; and/or, in step (2), the reaction temperature is -20°C to 150°C; and/or, step (3) ), the reaction temperature is -20°C to 150°C; and/or, in step (4), the reaction temperature is -20°C to 150°C;
- the reaction temperature is 20°C to 30°C; and/or, in step (2), the reaction temperature is 60°C to 80°C; and/or, in step (3) , the reaction temperature is 20°C to 30°C; and/or, in step (4), the reaction temperature is 20°C to 30°C.
- R 1 is hydrogen, ester group, silicon ester group, thiol ester group, tin ester group, amide group, hydrazine amide group, alkyl group, alkenyl group, alkynyl group, unsaturated aliphatic ring , aromatic ring, heterocyclic ring or aromatic heterocyclic ring;
- R 1 is hydrogen, ester group, silicon ester group, thiol ester group, tin ester group, amide group, hydrazine amide group, C 1 -C 6 alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 alkynyl, unsaturated aliphatic ring, aromatic ring, heterocycle or aromatic heterocycle;
- R 1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, N,N- Diethylaminoethyl, allyl, propynyl, unsaturated aliphatic, aromatic, heterocyclic or aromatic heterocycle;
- R 1 is hydrogen, methyl, ethyl, or tert-butyl.
- the base is triethylamine, diethylamine, N,N-diisopropylethylamine, triethylenediamine, 4-dimethylaminopyridine, N,N-dimethylamine aniline, 1,8-diazacyclo[5,4,0]undecene-7, pyridine, N-methylmorpholine, tetramethylethylenediamine, sodium carbonate, potassium carbonate, cesium carbonate, tertiary Potassium butoxide, sodium tert-butoxide, sodium methoxide or sodium ethoxide;
- the base is triethylamine.
- the solvent is any one or any of dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, acetonitrile, methanol, ethanol, isopropanol or tert-butanol Mixed solvents of various compositions;
- the solvent is a mixed solvent of ethylene dichloride and tert-butanol
- step (1) the volume ratio of the dichloroethane to tert-butanol is 1:1.
- R 2 is selected from methyl or deuterated methyl; and/or, in step (2), the base is triethylamine, diethylamine, N,N-diisopropyl Ethylethylamine, triethylenediamine, 4-dimethylaminopyridine, N,N-dimethylaniline, 1,8-diazacyclo[5,4,0]undecene-7, pyridine, N- Methylmorpholine, tetramethylethylenediamine, sodium carbonate, potassium carbonate, cesium carbonate, potassium tert-butoxide, sodium tert-butoxide, sodium methoxide or sodium ethoxide;
- the base is N,N-diisopropylethylamine.
- the solvent is methanol, ethanol, isopropanol, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone or two
- the solvent is N-methylpyrrolidone.
- the solvent used in the deprotection reaction is a mixture of any one or any multiple compositions in water, tetrahydrofuran, dioxane, methanol, ethanol, isopropanol or dichloromethane solvent;
- the solvent used in the deprotection reaction is dioxane.
- step (3) the deprotection reagent used in the deprotection reaction is acid or alkali;
- the deprotection reagent used in the deprotection reaction is hydrochloric acid, trifluoroacetic acid, lithium hydroxide, sodium hydroxide or potassium hydroxide;
- step (3) when R 1 is tert-butyl, the deprotection reagent used in the deprotection reaction is hydrochloric acid.
- R 5 is selected from methyl or deuterated methyl; and/or, in step (4), the amide condensation reaction is carried out in the presence of a condensing agent, and the condensing agent Selected from isopropyl chloroformate, N,N'-carbonyldiimidazole, p-toluenesulfonyl chloride, (Boc) 2O , dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide, O-(7-azabenzotriazole-1-yl)-bis(dimethylamino)carbonium hexafluorophosphate, O -(Benzotriazol-1-yl)-bis(dimethylamino)carbonium hexafluorophosphate, O-(5-chlorobenzotriazole-1-yl)-bis
- the condensing agent is selected from N,N'-carbonyldiimidazole;
- the molar ratio of the compound (V) and the condensing agent is (1-5): (1-5);
- the molar ratio of the compound (V) to the condensing agent is 1:1.1.
- the solvent used in the amide condensation reaction is an aprotic solvent
- the solvent used in the amide condensation reaction is dichloromethane, dichloroethane, acetone, diethyl ether, isopropyl ether, tetrahydrofuran, dioxane, toluene, acetonitrile, N,N- Dimethylformamide, N,N-dimethylacetamide or dimethyl sulfoxide;
- the solvent used in the amide condensation reaction is dichloromethane.
- Step A in a solvent, using compound (A) as a raw material, the compound (B) is prepared by substitution reaction with methanesulfonamide under the action of a base;
- Step B in a solvent, compound (B) is reacted with a methylating reagent under the action of a base to obtain compound (C), and R 2 is selected from C 1 -C 6 alkyl or C 1 -C 6 deuterated alkyl;
- Step C Compound (III) is prepared by reacting compound (C) with a reducing reagent, wherein R 3 and R 4 are independently selected from hydrogen or deuterium.
- step A the molar ratio of the compound (A), methanesulfonamide and base is (1-5):(1-5):(1-5);
- step B the molar ratio of the compound (B), the base and the methylating reagent is (1-2): (1-5): (1-3);
- step A the molar ratio of compound (A), methanesulfonamide and base is 2:3:4;
- step B the molar ratio of the compound (B), the base and the methylating agent is 1.5:4.5:2.3.
- step A the reaction temperature is -20°C to 150°C; and/or, in step B, the reaction temperature is -20°C to 150°C; and/or, in step C, the reaction The temperature is -20°C ⁇ 150°C;
- the reaction temperature is 80°C to 100°C; and/or, in step B, the reaction temperature is 60°C to 80°C; and/or in step C, the reaction temperature is 20°C ⁇ 30°C.
- the alkali is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, potassium tert-butoxide, tertiary Sodium butoxide, sodium methoxide, sodium ethoxide, triethylamine, diethylamine, N,N-diisopropylethylamine, triethylenediamine, 4-dimethylaminopyridine, N,N-dimethylaniline, 1,8-diazacyclo[5,4,0]undecene-7, pyridine, N-methylmorpholine or tetramethylethylenediamine;
- the base is cesium carbonate.
- the solvent is methanol, ethanol, isopropanol, ethyl acetate, dichloromethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dichloromethane methyl sulfoxide, N-methylpyrrolidone, tetrahydrofuran, toluene, dichloromethane, dioxane or water;
- the solvent is acetonitrile.
- R is selected from methyl or deuterated methyl; and/or, in step B, the alkali used is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, hydroxide Sodium, potassium hydroxide, lithium hydroxide, calcium hydroxide, potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, sodium ethoxide, triethylamine, diethylamine, N,N-diisopropylethylamine, triethylamine Ethylenediamine, 4-dimethylaminopyridine, N,N-dimethylaniline, 1,8-diazacyclo[5,4,0]undecene-7, pyridine, N-methylmorpholine or Tetramethylethylenediamine;
- the base is potassium carbonate.
- the methylating reagent is non-deuterated or deuterated methanol, methyl iodide, dimethyl sulfate, methyl p-toluenesulfonate, methyl p-nitrobenzenesulfonate, trimethylbenzene Methyl fluoromethanesulfonate, dimethyl carbonate, trimethyl phosphite, dimethyl phosphite, trimethyl phosphate, dimethyl phosphite, trimethyl orthoformate, trimethyl orthoacetate, methanesulfonyl Methylamine, diazomethane;
- the methylating reagents are methyl iodide and deuterated methyl iodide.
- the solvent used is methanol, ethanol, isopropanol, ethyl acetate, dichloromethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, two methyl sulfoxide, N-methylpyrrolidone, tetrahydrofuran, toluene, dichloromethane, dioxane or water;
- the solvent used is acetonitrile or N,N-dimethylformamide.
- the reducing reagent used is lithium aluminum hydride, diisobutyl aluminum hydride, sodium borohydride, lithium borohydride, zinc borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, Lithium ethylborohydride, lithium triisobutylborohydride, lithium N,N-dimethylaminoborohydride, dimethoxyethoxyaluminum hydride, dicarbonyldicyclopentadienyl titanium, borane, dimethyl borane sulfide, triethylsilane, zinc-acetic acid, hydrogen or deuterium;
- the reducing reagent used is hydrogen or deuterium.
- step C a catalyst is used during the reaction, and the catalyst is a transition metal catalyst
- the catalyst is Raney Ni, palladium carbon or platinum carbon;
- the catalyst is Raney Ni.
- the solvent used during the reaction is methanol, ethanol, isopropanol, tert-butanol, ether, tetrahydrofuran, toluene, dichloromethane, dioxane or any one or more in water composed of mixed solvents;
- the solvent used in the reaction is methanol.
- the room temperature is 25 ⁇ 5°C; overnight is 12 ⁇ 2h.
- an unsaturated aliphatic ring refers to a cyclic compound having one or more double bonds or triple bonds without a heteroatom
- an aromatic ring refers to a compound having an aromatic ring structure
- a heterocyclic ring has one or more Cyclic compounds of heteroatoms
- aromatic heterocycles refer to compounds having one or more heteroatoms and having an aromatic ring structure.
- the invention provides a method for synthesizing aminopyrimidine FAK inhibitor compounds.
- the method is easy to operate and low in cost; however, the prepared product can obtain a high total yield (the total yield of the shortest linear route from commercial raw materials is 66%) %) and purity ( ⁇ 99%), the product yield and purity are better than those of the prior art (the yield of the prior art is always about 11%, and the purity is 99%).
- the synthesis method of the invention achieves excellent effects, and can also successfully prepare a kilogram-level final product, which is suitable for technological production and has good application prospects.
- the raw materials and equipment used in the specific embodiments of the present invention are all known products, which are obtained by purchasing commercially available products.
- the temperature is expressed in degrees Celsius (°C), and the operation is carried out at room temperature or in a temperature environment;
- the organic solvent is dried with anhydrous sodium sulfate, and the solvent is evaporated with a rotary evaporator Distilled under reduced pressure, the bath temperature was not higher than 60°C;
- the reaction process was followed by thin layer chromatography (TLC) or LCMS.
- Step A Preparation of N-(3-cyanopyrazin-2-yl)methanesulfonamide (Intermediate B)
- Step B Preparation of N-(3-cyanopyrazin-2-yl)-N-(methyl)methanesulfonamide (Intermediate C-1)
- Step C Preparation of N-(3-(aminomethyl)pyrazin-2-yl)-N-(methyl)methanesulfonamide (Intermediate III-1)
- Step 1 Preparation of tert-butyl 4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzoate (Intermediate II-1)
- the raw material 2,4-dichloro-5-trifluoromethylpyrimidine (4.56 g, 21 mmol) was dissolved in 100 mL of a mixed solvent of dichloroethane/tert-butanol (1/1, v/v), under nitrogen protection
- the ice-water bath was cooled, zinc bromide (13.5g, 60mmol) was added, stirring was continued for 30 minutes, and tert-butyl 4-aminobenzoate (raw material I-1) (3.86g, 20mmol) and triethylamine (6.46g) were added in turn. , 64mmol), remove the external bath, and naturally return to the temperature for overnight reaction.
- Step 2 4-((4-((3-(N-(methyl)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine-2 Preparation of -yl)amino) tert-butyl benzoate (intermediate IV-1)
- Step 3 4-((4-((3-(N-(methyl)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine-2 Preparation of -yl)amino)benzoic acid (Intermediate V-1)
- Step 4 N-(methyl)-4-((4-((3-(N-(methyl)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(tris Preparation of Fluoromethyl)pyrimidin-2-yl)amino)benzamide (target compound VII-1)
- Triethylamine (202 mg, 2.0 mmol) and methylamine hydrochloride (raw material VI-1) (16 mg, 0.22 mmol) were added in sequence, and the reaction was stirred at room temperature for 2 hours.
- Step B Preparation of N-(3-cyanopyrazin-2-yl)-N-(methyl-d3)methanesulfonamide (Intermediate C-2)
- the intermediate C-2 was prepared with the reaction conditions similar to Example 1, step B, and the yield was 80%.
- Step C Preparation of N-(3-(Aminomethyl)pyrazin-2-yl)-N-(methyl-d3)methanesulfonamide (Intermediate III-2)
- Step 2 4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine
- Step 2 4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine
- intermediate IV-2 was prepared with a yield of 76%.
- Step 3 4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine Preparation of -2-yl)amino)benzoic acid (Intermediate V-2)
- Step 4 N-(methyl-d3)-4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)- Preparation of 5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide (VII-2)
- Step A 4-((4-((3-(N-(methyl)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine-2 Preparation of -yl)amino) tert-butyl benzoate (intermediate IV-2)
- Step B 4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidine Preparation of -2-yl)amino)benzoic acid (Intermediate V-2)
- Step C N-(methyl-d3)-4-((4-((3-(N-(methyl-d3)methylsulfonamido)pyrazin-2-yl)methyl)amino)- Preparation of 5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide (VII-2)
- the present invention provides a method for synthesizing aminopyrimidine FAK inhibitor compounds, which is easy to operate and low in cost; the prepared product can obtain high total yield ( ⁇ 66%) and purity ( ⁇ 66%) 99%), the product yield and purity are better than the prior art (the yield of the prior art is always about 11%, and the purity is 99%).
- the synthesis method of the invention achieves excellent effects, and can also successfully prepare a kilogram-level final product, which is suitable for technological production and has good application prospects.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (23)
- 根据权利要求1所述的方法,其特征在于:步骤(1)中,所述化合物(I)、2,4-二氯-5-(三氟甲基)嘧啶和碱的摩尔比为(1~3):(1~3):(1~7);和/或,步骤(2)中,所述化合物(II)、化合物(III)和碱的摩尔比为(1~5):(0.1~1):(1~5);和/或,步骤(4)中,所述(V)和化合物(VI)的摩尔比为(1~5):(1~5);优选地,步骤(1)中,所述化合物(I)、2,4-二氯-5-(三氟甲基)嘧啶和碱的摩尔比为2.0:2.1:6.4;和/或,步骤(2)中,所述化合物(II)、化合物(III)和碱的摩尔比为1:0.5:1.5;和/或,步骤(4)中,所述(V)和化合物(VI)的摩尔比为1:1.1。
- 根据权利要求1所述的方法,其特征在于:步骤(1)中,所述反应 温度为-20℃~150℃;和/或,步骤(2)中,所述反应温度为-20℃~150℃;和/或,步骤(3)中,所述反应温度为-20℃~150℃;和/或,步骤(4)中,所述反应温度为-20℃~150℃;优选地,步骤(1)中,所述反应温度为20℃~30℃;和/或,步骤(2)中,所述反应温度为60℃~80℃;和/或,步骤(3)中,所述反应温度为20℃~30℃;和/或,步骤(4)中,所述反应温度为20℃~30℃。
- 根据权利要求1所述的方法,其特征在于:步骤(1)中,R 1为氢、酯基、硅酯基、硫醇酯基、锡酯基、酰胺基、肼酰胺基、烷基、烯基、炔基、不饱和脂肪环、芳环、杂环或芳杂环;优选地,步骤(1)中,R 1为氢、酯基、硅酯基、硫醇酯基、锡酯基、酰胺基、肼酰胺基、C 1~C 6烷基、C 2~C 6烯基、C 2~C 6炔基、不饱和脂肪环、芳环、杂环或芳杂环;更优选地,步骤(1)中,R 1为氢、甲基、乙基、正丙基、异丙基、正丁基、仲丁基、叔丁基、戊基、己基、N,N-二乙基氨基乙基、烯丙基、丙炔基、不饱和脂肪环、芳环、杂环或芳杂环;进一步优选地,步骤(1)中,R 1为氢、甲基、乙基、叔丁基。
- 根据权利要求1所述的方法,其特征在于:步骤(1)中,所述碱为三乙胺、二乙胺、N,N-二异丙基乙胺、三乙烯二胺、4-二甲氨基吡啶、N,N-二甲基苯胺、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、N-甲基吗啉、四甲基乙二胺、碳酸钠、碳酸钾、碳酸铯、叔丁醇钾、叔丁醇钠,甲醇钠或乙醇钠;优选地,步骤(1)中,所述碱为三乙胺。
- 根据权利要求1所述的方法,其特征在于:步骤(1)中,所述溶剂为二氯甲烷、三氯甲烷、四氯化碳、二氯乙烷、乙腈、甲醇、乙醇、异丙醇或叔丁醇中任意一种或任意多种组成的混合溶剂;优选地,步骤(1)中,所述溶剂为二氯乙烷与叔丁醇的混合溶剂;更优选地,步骤(1)中,所述二氯乙烷与叔丁醇的体积比为1:1。
- 根据权利要求1所述的方法,其特征在于:步骤(2)中,R 2选自甲基或氘代甲基;和/或,步骤(2)中,所述碱为三乙胺、二乙胺、N,N-二异丙基乙胺、三乙烯二胺、4-二甲氨基吡啶、N,N-二甲基苯胺、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、N-甲基吗啉、四甲基乙二胺、碳酸钠、碳酸钾、碳酸铯、叔丁醇钾、叔丁醇钠,甲醇钠或乙醇钠;优选地,步骤(2)中,所述碱为N,N-二异丙基乙胺。
- 根据权利要求1所述的方法,其特征在于:步骤(2)中,所述溶剂为甲醇、乙醇、异丙醇、乙腈、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮或二甲基亚砜中任意一种或任意多种组成的混合溶剂;优选地,步骤(2)中,所述溶剂为N-甲基吡咯烷酮。
- 根据权利要求1所述的方法,其特征在于:步骤(3)中,所述脱保护反应中使用的溶剂为水、四氢呋喃、二氧六环、甲醇、乙醇、异丙醇或二氯甲烷中任意一种或任意多种组成的混合溶剂;优选地,步骤(3)中,所述脱保护反应中使用的溶剂为二氧六环。
- 根据权利要求1所述的方法,其特征在于:步骤(3)中,所述脱保护反应中使用的脱保护试剂为酸或碱;优选地,步骤(3)中,所述脱保护反应中使用的脱保护试剂为氢氯酸、三氟乙酸、氢氧化锂、氢氧化钠或氢氧化钾;更优选地,步骤(3)中,当R 1为叔丁基时,脱保护反应中使用的脱保护试剂为氢氯酸。
- 根据权利要求1所述的方法,其特征在于:步骤(4)中,R 5选自甲基或氘代甲基;和/或,步骤(4)中,所述酰胺缩合反应是在缩合剂的存在下进行的,所述缩合剂选自氯甲酸异丙酯、N,N’-羰基二咪唑、对甲苯磺酰氯、(Boc) 2O、二环己基碳二亚胺、二异丙基碳二亚胺、1-(3-二甲胺基丙基)-3-乙基碳二亚胺、O-(7-氮杂苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(5-氯苯并三氮唑-1-基)-二(二甲胺基)碳鎓六氟磷酸盐、O-(苯并三氮唑-1-基)-二(二甲胺基)碳鎓四氟硼酸盐、O-(N-丁二酰亚胺基)-二(二甲胺基)碳鎓四氟硼酸盐、O-(N-endo-5-降莰烯-2,3-二碳二酰亚胺)-二(二甲胺基)碳鎓四氟硼酸盐、苯并三氮唑-1-基氧-三(二甲胺基)鏻鎓六氟磷酸盐、苯并三氮唑-1-基氧-三(四氢吡咯基)鏻鎓六氟磷酸盐、二苯基磷酰氯、氰代磷酸二乙酯、叠氮化磷酸二苯酯、硫代二甲基磷酰基叠氮或二(2-氧-3-唑烷基)磷酰氯;优选地,步骤(4)中,所述缩合剂选自N,N’-羰基二咪唑;更优选地,所述化合物(V)和缩合剂的摩尔比为(1~5):(1~5);进一步优选地,所述化合物(V)和缩合剂的摩尔比为1:1.1。
- 根据权利要求1所述的方法,其特征在于:步骤(4)中,所述酰胺缩合反应使用的溶剂为非质子性溶剂;优选地,步骤(4)中,所述酰胺缩合反应使用的溶剂为二氯甲烷、二氯乙烷、丙酮、乙醚、异丙醚、四氢呋喃、二氧六环、甲苯、乙腈、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺或二甲亚砜;更优选地,步骤(4)中,所述酰胺缩合反应使用的溶剂为二氯甲烷。
- 根据权利要求13所述的方法,其特征在于:步骤A中,所述化合物(A)、甲磺酰胺和碱的摩尔比为(1~5):(1~5):(1~5);和/或,步骤B中,所述化合物(B)、碱和甲基化试剂的摩尔比为(1~2):(1~5):(1~3);优选地,步骤A中,所述化合物(A)、甲磺酰胺和碱的摩尔比为2:3:4;和/或,步骤B中,所述化合物(B)、碱和甲基化试剂的摩尔比为1.5:4.5:2.3。
- 根据权利要求13所述的方法,其特征在于:步骤A中,所述反应温度为-20℃~150℃;和/或,步骤B中,所述反应温度为-20℃~150℃;和/或,步骤C中,所述反应温度为-20℃~150℃;优选地,步骤A中,所述反应温度为80℃~100℃;和/或,步骤B中,所述反应温度为60℃~80℃;和/或,步骤C中,所述反应温度为20℃~30℃。
- 根据权利要求13所述的方法,其特征在于:步骤A中,所述碱为碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂、氢氧化钙、叔丁醇钾、叔丁醇钠、甲醇钠、乙醇钠、三乙胺、二乙胺、N,N-二异丙基乙胺、三乙烯二胺、4-二甲氨基吡啶、N,N-二甲基苯胺、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、N-甲基吗啉或四甲基乙二胺;优选地,所述碱为碳酸铯。
- 根据权利要求13所述的方法,其特征在于:步骤A中,所述溶剂为甲醇、乙醇、异丙醇、乙酸乙酯、二氯甲烷、乙腈、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、N-甲基吡咯烷酮、四氢呋喃、甲苯、二氯甲烷、二氧六环或水;优选地,步骤(A)中,所述溶剂为乙腈。
- 根据权利要求13所述的方法,其特征在于:步骤B中,R 2选自甲基或氘代甲基;和/或,步骤B中,所用的碱为碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂、氢氧化钙、叔丁醇钾、叔丁醇钠、甲醇钠、乙醇钠、三乙胺、二乙胺、N,N-二异丙基乙胺、三乙烯二胺、4-二甲氨基吡啶、N,N-二甲基苯胺、1,8-二氮杂环[5,4,0]十一烯-7、吡啶、N-甲基吗啉或四甲基乙二胺;优选地,所述碱为碳酸钾。
- 根据权利要求13所述的方法,其特征在于:步骤B中,所述甲基化试剂为非氘代或氘代的甲醇、碘甲烷、硫酸二甲酯、对甲基苯磺酸甲酯、对硝基苯磺酸甲酯、三氟甲磺酸甲酯、碳酸二甲酯、亚磷酸三甲酯、亚磷酸二甲酯、磷酸三甲酯、亚磷酸二甲酯、原甲酸三甲酯、原乙酸三甲酯、甲磺酰甲胺、重氮甲烷;优选地,步骤B中,所述甲基化试剂为碘甲烷和氘代碘甲烷。
- 根据权利要求13所述的方法,其特征在于:步骤B中,所用的溶剂为甲醇、乙醇、异丙醇、乙酸乙酯、二氯甲烷、乙腈、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、N-甲基吡咯烷酮、四氢呋喃、甲苯、二氯甲烷、二氧六环或水;优选地,所用的溶剂为乙腈或N,N-二甲基甲酰胺。
- 根据权利要求13所述的方法,其特征在于:步骤C中,所用的还原试剂为氢化铝锂、二异丁基氢化铝、硼氢化钠、硼氢化锂、硼氢化锌、三乙酰氧基硼氢化钠、氰基硼氢化钠、三乙基硼氢化锂、三异丁基硼氢化锂、N,N-二甲氨基硼氢化锂、二甲氧基乙氧基氢化铝、二羰基二环戊二烯基钛、硼烷、二甲基硫化硼烷、三乙基硅烷、锌-乙酸、氢气或氘气;优选地,步骤C中,所用的还原试剂为氢气或氘气。
- 根据权利要求13所述的方法,其特征在于:步骤C中,所述反应时使用催化剂,所述催化剂为过渡金属催化剂;优选地,步骤C中,所述催化剂为Raney Ni、钯碳或铂碳;更优选地,步骤C中,所述催化剂为Raney Ni。
- 根据权利要求13所述的方法,其特征在于:步骤C中,所述反应时使用的溶剂为甲醇、乙醇、异丙醇、叔丁醇、乙醚、四氢呋喃、甲苯、二氯甲烷、二氧六环或水中任意一种或任意多种组成的混合溶剂;优选地,步骤C中,所述反应时使用的溶剂为甲醇。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22739190.1A EP4279488A1 (en) | 2021-01-18 | 2022-01-18 | Synthesis method for aminopyrimidine fak inhibitor compound |
AU2022207035A AU2022207035A1 (en) | 2021-01-18 | 2022-01-18 | Synthesis method for aminopyrimidine fak inhibitor compound |
US18/261,057 US20240059678A1 (en) | 2021-01-18 | 2022-01-18 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound |
JP2023542733A JP2024503855A (ja) | 2021-01-18 | 2022-01-18 | アミノピリミジン系fak阻害剤化合物を合成する方法 |
CA3208625A CA3208625A1 (en) | 2021-01-18 | 2022-01-18 | Synthesis method for aminopyrimidine fak inhibitor compound |
KR1020237022875A KR20230117416A (ko) | 2021-01-18 | 2022-01-18 | 아미노피리미딘계 fak 억제제 화합물의 합성 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110063534 | 2021-01-18 | ||
CN202110063534.9 | 2021-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022152315A1 true WO2022152315A1 (zh) | 2022-07-21 |
Family
ID=82446962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/072552 WO2022152315A1 (zh) | 2021-01-18 | 2022-01-18 | 一种合成氨基嘧啶类fak抑制剂化合物的方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240059678A1 (zh) |
EP (1) | EP4279488A1 (zh) |
JP (1) | JP2024503855A (zh) |
KR (1) | KR20230117416A (zh) |
CN (1) | CN114805308A (zh) |
AU (1) | AU2022207035A1 (zh) |
CA (1) | CA3208625A1 (zh) |
WO (1) | WO2022152315A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115304460A (zh) * | 2022-08-16 | 2022-11-08 | 深圳鼎邦生物科技有限公司 | 一种癸醛-1,2,2,3,3-d5的合成方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171359A1 (en) * | 2001-10-17 | 2003-09-11 | Boehringer Ingelheim Pharma Kg | Pyrimidine derivatives |
CN101541801A (zh) * | 2006-08-04 | 2009-09-23 | 武田药品工业株式会社 | 稠杂环衍生物及其用途 |
CN101678215A (zh) * | 2007-04-18 | 2010-03-24 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
CN103848851A (zh) * | 2012-11-29 | 2014-06-11 | 上海交通大学 | 一种盐酸头孢卡品酯的合成方法 |
CN106316889A (zh) * | 2015-06-15 | 2017-01-11 | 上海阳帆医药科技有限公司 | 依度沙班中间体的制备方法 |
CN110452229A (zh) | 2018-05-07 | 2019-11-15 | 成都海创药业有限公司 | 氘代Defactinib化合物及其用途 |
CN111377871A (zh) | 2018-12-27 | 2020-07-07 | 成都海创药业有限公司 | 一种fak抑制剂及其联合用药物 |
CN111377873A (zh) * | 2018-12-28 | 2020-07-07 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
-
2022
- 2022-01-18 CN CN202210055918.0A patent/CN114805308A/zh active Pending
- 2022-01-18 WO PCT/CN2022/072552 patent/WO2022152315A1/zh active Application Filing
- 2022-01-18 US US18/261,057 patent/US20240059678A1/en active Pending
- 2022-01-18 KR KR1020237022875A patent/KR20230117416A/ko unknown
- 2022-01-18 EP EP22739190.1A patent/EP4279488A1/en active Pending
- 2022-01-18 CA CA3208625A patent/CA3208625A1/en active Pending
- 2022-01-18 JP JP2023542733A patent/JP2024503855A/ja active Pending
- 2022-01-18 AU AU2022207035A patent/AU2022207035A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171359A1 (en) * | 2001-10-17 | 2003-09-11 | Boehringer Ingelheim Pharma Kg | Pyrimidine derivatives |
CN101541801A (zh) * | 2006-08-04 | 2009-09-23 | 武田药品工业株式会社 | 稠杂环衍生物及其用途 |
CN101678215A (zh) * | 2007-04-18 | 2010-03-24 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
CN103848851A (zh) * | 2012-11-29 | 2014-06-11 | 上海交通大学 | 一种盐酸头孢卡品酯的合成方法 |
CN106316889A (zh) * | 2015-06-15 | 2017-01-11 | 上海阳帆医药科技有限公司 | 依度沙班中间体的制备方法 |
CN110452229A (zh) | 2018-05-07 | 2019-11-15 | 成都海创药业有限公司 | 氘代Defactinib化合物及其用途 |
CN111377871A (zh) | 2018-12-27 | 2020-07-07 | 成都海创药业有限公司 | 一种fak抑制剂及其联合用药物 |
CN111377873A (zh) * | 2018-12-28 | 2020-07-07 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115304460A (zh) * | 2022-08-16 | 2022-11-08 | 深圳鼎邦生物科技有限公司 | 一种癸醛-1,2,2,3,3-d5的合成方法 |
CN115304460B (zh) * | 2022-08-16 | 2024-02-13 | 深圳鼎邦生物科技有限公司 | 一种癸醛-1,2,2,3,3-d5的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
US20240059678A1 (en) | 2024-02-22 |
AU2022207035A1 (en) | 2023-09-07 |
EP4279488A1 (en) | 2023-11-22 |
JP2024503855A (ja) | 2024-01-29 |
KR20230117416A (ko) | 2023-08-08 |
CN114805308A (zh) | 2022-07-29 |
CA3208625A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI715658B (zh) | 二氫嘧啶並環化合物的晶型、製備方法和中間體 | |
CA2960733C (en) | Processes and intermediates in the preparation of c5ar antagonists | |
CN102985416B (zh) | 制备凝血酶特异性抑制剂的方法 | |
WO2008062859A1 (fr) | Procédé de fabrication de dérivés de phénylalanine ayant des squelettes de quinazolinedione et intermédiaires pour la fabrication | |
ES2769255T3 (es) | Métodos para fabricar inhibidores de la proteína desacetilasa | |
JP6268093B2 (ja) | 縮合複素環誘導体の製造方法およびその製造中間体 | |
EP3199536B1 (en) | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof | |
WO2014154723A1 (en) | Novel pyrrole derivatives for the treatment of cancer | |
CN107810189B (zh) | 用于制备氮芥衍生物的方法 | |
WO2022152315A1 (zh) | 一种合成氨基嘧啶类fak抑制剂化合物的方法 | |
DK2462126T3 (en) | Process for stereoselective synthesis of bicyclic heterocyclic compounds. | |
TWI541235B (zh) | 製備喹唑啉衍生物之方法 | |
WO2016124144A1 (zh) | 布瑞哌唑类似物的制备方法 | |
US8093384B2 (en) | Processes for the preparation of alfuzosin | |
EP4073051B1 (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
CN104418845B (zh) | 制备拉帕替尼的方法和中间体 | |
WO2023246807A1 (zh) | 杰克替尼二盐酸盐一水合物的制备工艺 | |
RU2503655C2 (ru) | N-(5-АЦЕТИЛ-2-ФТОРФЕНИЛ)-N-МЕТИЛАЦЕТАМИД, СПОСОБ ПОЛУЧЕНИЯ N-[5-(3-ДИМЕТИЛАМИНО-АКРИЛОИЛ)-2-ФТОРФЕНИЛ]-N-МЕТИЛАЦЕТАМИДА И СПОСОБ ПОЛУЧЕНИЯ N-{2-ФТОР-5-[3-ТИОФЕН-2-КАРБОНИЛ-ПИРАЗОЛО [1,5-а]ПИРИМИДИН-7-ИЛ]ФЕНИЛ}-N-МЕТИЛАЦЕТАМИДА | |
KR101037052B1 (ko) | 5-클로로-n-(((5s)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4h)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 | |
WO2024011450A1 (en) | Synthetic methods for preparing a pyridinecarboxamide compound | |
TW202039430A (zh) | 製備磺胺類藥物的方法 | |
CA2723133A1 (en) | Process for production of compound having antagonistic activity on npyy5 receptor, and useful crystal | |
JPWO2006025480A1 (ja) | 7−置換カルボスチリル誘導体及びその製造方法 | |
CN108368050A (zh) | 制备巴豆酰基氨基吡啶的改进方法 | |
NO326697B1 (no) | Nye 1,3,5-triazinderivater som ligander for humane adenosin-A3-reseptorer, og farmasøytiske sammensetninger som inneholder slike |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22739190 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20237022875 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18261057 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023542733 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3208625 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023013989 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023013989 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230712 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022207035 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022739190 Country of ref document: EP Effective date: 20230818 |
|
ENP | Entry into the national phase |
Ref document number: 2022207035 Country of ref document: AU Date of ref document: 20220118 Kind code of ref document: A |